uniQure prices upsized $225 million underwritten offering of 4.95 million ordinary shares at $45.50
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.12M | $15.84M | $106.48M | $524.00M | $37.51M | $7.28M | $11.28M | $13.11M |
| Cost of Revenue | $18.33M | $13.63M | $3.34M | $24.98M | $122.40M | N/A | $73.06M | $67.41M |
| Gross Profit | $8.79M | $2.21M | $103.14M | $499.03M | $-84.89M | $7.28M | $-61.78M | $-54.30M |
| Gross Margin | 32.42% | 13.98% | 96.86% | 95.23% | -226.28% | 100.00% | -547.47% | -414.30% |
| Operating Expenses | $193.09M | $285.09M | $246.30M | $188.41M | $40.54M | $128.42M | $26.46M | $17.66M |
| Operating Income | $-184.29M | $-282.87M | $-143.16M | $310.62M | $-125.43M | $-121.14M | $-88.23M | $-71.96M |
| Operating Margin | -679.58% | -1785.46% | -134.44% | 59.28% | -334.34% | -1663.78% | -781.92% | -549.00% |
| Net Income | $-239.56M | $-308.48M | $-126.79M | $329.59M | $-125.02M | $-124.20M | $-83.30M | $-80.39M |
| Net Margin | -883.35% | -1947.09% | -119.07% | 62.90% | -333.27% | -1705.82% | -738.25% | -613.33% |
| EPS (Basic) | $-4.92 | $-6.47 | $-2.71 | $7.17 | $-2.81 | $-3.20 | $-2.34 | $-2.98 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |